USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC KIDNEY DISEASE - CLINICAL EXPERIENCE OF BULGARIAN PEDIATRIC GROUP
Darbepoetin alfa (DA) is indicated for treatment of symptomatic anemia related to chronic kidney disease (CKD) in adult and pediatric patients. In comparison with the recombinant human erythropoietin (rHuEpo), darbepoetin alfa has two additional carbohydrates containing sialic acid which prolong its...
Saved in:
Main Authors: | Maria Gaydarova (Author), Anelia Boueva (Author), Svetlana Marinova (Author), Galina Zlatanova (Author) |
---|---|
Format: | Book |
Published: |
Peytchinski Publishing,
2017-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic analysis of using the darbepoetin alfa to correct anemia in patients with chronic renal failure who are on hemodialysis or peritoneal dialysis
by: I. S. Krysanov, et al.
Published: (2018) -
Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
by: Derbyshire L, et al.
Published: (2013) -
Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis
by: Geo Neul Park, et al.
Published: (2024) -
Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes
by: Tarun Kumar Jeloka, et al.
Published: (2020) -
Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature
by: Anna Maria Libudzic-Nowak, et al.
Published: (2018)